Market Closed -
Nasdaq
21:00:00 28/06/2024 BST
|
5-day change
|
1st Jan Change
|
2.57
USD
|
-0.39%
|
|
-3.38%
|
-70.76%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
821.4
|
1,886
|
1,172
|
1,519
|
771.9
|
268.4
|
-
|
-
|
Enterprise Value (EV)
1 |
531.3
|
1,630
|
1,172
|
1,519
|
1,064
|
494.8
|
492.9
|
475.7
|
P/E ratio
|
-4.42
x
|
-5.83
x
|
-3.91
x
|
-3.77
x
|
-2.3
x
|
-1.33
x
|
-2.9
x
|
-18.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,989
x
|
123
x
|
15.1
x
|
11.5
x
|
3.3
x
|
0.97
x
|
0.72
x
|
0.57
x
|
EV / Revenue
|
1,286
x
|
106
x
|
15.1
x
|
11.5
x
|
4.54
x
|
1.78
x
|
1.32
x
|
1
x
|
EV / EBITDA
|
-3.29
x
|
-6.2
x
|
-4.6
x
|
-4.93
x
|
-6.65
x
|
-5.96
x
|
-34.1
x
|
8.12
x
|
EV / FCF
|
-4.81
x
|
-8.93
x
|
-5.05
x
|
-7.72
x
|
-4.76
x
|
-3.95
x
|
-11
x
|
11.2
x
|
FCF Yield
|
-20.8%
|
-11.2%
|
-19.8%
|
-13%
|
-21%
|
-25.3%
|
-9.13%
|
8.89%
|
Price to Book
|
-
|
-
|
-
|
-
|
-5.1
x
|
-1.66
x
|
-1.42
x
|
-1.7
x
|
Nbr of stocks (in thousands)
|
50,608
|
66,549
|
71,795
|
82,274
|
87,813
|
104,449
|
-
|
-
|
Reference price
2 |
16.23
|
28.34
|
16.32
|
18.46
|
8.790
|
2.570
|
2.570
|
2.570
|
Announcement Date
|
24/02/20
|
22/02/21
|
28/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.413
|
15.32
|
77.8
|
132.6
|
234
|
278.1
|
372.3
|
474.6
|
EBITDA
1 |
-161.6
|
-262.9
|
-254.8
|
-308.2
|
-160.1
|
-83.04
|
-14.45
|
58.57
|
EBIT
1 |
-164.5
|
-273.2
|
-274.7
|
-342
|
-316.8
|
-173.2
|
-82.6
|
-1.315
|
Operating Margin
|
-39,820.58%
|
-1,782.46%
|
-353.06%
|
-257.95%
|
-135.35%
|
-62.28%
|
-22.19%
|
-0.28%
|
Earnings before Tax (EBT)
1 |
-159.4
|
-284.7
|
-281.3
|
-355.7
|
-323.7
|
-193.6
|
-93.53
|
-25.88
|
Net income
1 |
-159.4
|
-282.1
|
-281.3
|
-356.4
|
-324
|
-190.4
|
-89.83
|
-18.66
|
Net margin
|
-38,602.66%
|
-1,840.71%
|
-361.59%
|
-268.87%
|
-138.43%
|
-68.49%
|
-24.13%
|
-3.93%
|
EPS
2 |
-3.670
|
-4.860
|
-4.170
|
-4.900
|
-3.830
|
-1.935
|
-0.8860
|
-0.1400
|
Free Cash Flow
1 |
-110.5
|
-182.6
|
-231.9
|
-196.8
|
-223.5
|
-125.1
|
-45
|
42.3
|
FCF margin
|
-26,766.59%
|
-1,191.52%
|
-298.1%
|
-148.42%
|
-95.48%
|
-44.99%
|
-12.09%
|
8.91%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
72.22%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/02/20
|
22/02/21
|
28/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
25.95
|
25.26
|
28.37
|
29.02
|
49.92
|
49.33
|
58.13
|
56.78
|
69.8
|
51.94
|
66.29
|
68.76
|
88.73
|
80.55
|
89.9
|
EBITDA
|
-56.18
|
-56.84
|
-52.39
|
-72.04
|
-126.9
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-61.6
|
-62.22
|
-57.84
|
-77.48
|
-144.4
|
-58.03
|
-65.5
|
-139.3
|
-53.95
|
-46.83
|
-43.62
|
-40.99
|
-38.99
|
-
|
-
|
Operating Margin
|
-237.39%
|
-246.31%
|
-203.9%
|
-267.05%
|
-289.28%
|
-117.64%
|
-112.67%
|
-245.34%
|
-77.3%
|
-90.16%
|
-65.8%
|
-59.62%
|
-43.94%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-63.1
|
-64.34
|
-61.44
|
-83.99
|
-146
|
-59.79
|
-67.32
|
-140.9
|
-55.7
|
-49.52
|
-47.07
|
-41.19
|
-46.32
|
-
|
-
|
Net income
1 |
-63.1
|
-64.34
|
-61.44
|
-84.69
|
-146
|
-59.79
|
-67.32
|
-141.2
|
-55.7
|
-53.15
|
-47.07
|
-41.53
|
-45.99
|
-
|
-
|
Net margin
|
-243.15%
|
-254.71%
|
-216.56%
|
-291.89%
|
-292.37%
|
-121.21%
|
-115.8%
|
-248.65%
|
-79.8%
|
-102.34%
|
-71%
|
-60.4%
|
-51.83%
|
-
|
-
|
EPS
2 |
-0.9300
|
-0.9400
|
-0.8800
|
-1.170
|
-1.900
|
-0.7400
|
-0.8000
|
-1.630
|
-0.6200
|
-0.5800
|
-0.4825
|
-0.4450
|
-0.4500
|
-0.2700
|
-0.2000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/22
|
10/05/22
|
09/08/22
|
08/11/22
|
28/02/23
|
09/05/23
|
08/08/23
|
08/11/23
|
28/02/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
292
|
226
|
224
|
207
|
Net Cash position
1 |
290
|
256
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-1.823
x
|
-2.725
x
|
-15.53
x
|
3.538
x
|
Free Cash Flow
1 |
-111
|
-183
|
-232
|
-197
|
-223
|
-125
|
-45
|
42.3
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-879%
|
-
|
-
|
-
|
11.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
-1.720
|
-1.550
|
-1.810
|
-1.510
|
Cash Flow per Share
|
-
|
-
|
-
|
-2.660
|
-2.560
|
-
|
-
|
-
|
Capex
1 |
3.24
|
4.1
|
10.4
|
3.21
|
6.89
|
8.33
|
9.33
|
10.3
|
Capex / Sales
|
784.02%
|
26.74%
|
13.34%
|
2.42%
|
2.94%
|
3%
|
2.51%
|
2.18%
|
Announcement Date
|
24/02/20
|
22/02/21
|
28/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
2.57
USD Average target price
13.5
USD Spread / Average Target +425.29% Consensus |
1st Jan change
|
Capi.
|
---|
| -70.76% | 268M | | +2.99% | 95.18B | | -4.34% | 37.55B | | -10.41% | 33.75B | | +75.79% | 28.2B | | -14.61% | 15.63B | | -3.46% | 13.63B | | -12.31% | 11.5B | | +184.77% | 10.81B | | -54.13% | 9.23B |
Biopharmaceuticals
|